Clinical trial · Interventional
Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer
Exploration of the Neuromuscular Mechanisms Associated With Sunitinib Related Fatigue
NCT01740154CI-TRIAL-00036047terminatedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Slow Accrual
Summary
Brief summary (as posted)
The purpose of this research study is to determine how sunitinib (sunitinib malate) causes fatigue. Patients will be asked to complete a brief questionnaire (survey) to rate their levels of fatigue every two weeks while they are participating in this research study. The questionnaire takes approximately 10-15 minutes to complete and is 9 questions. A series of physical measurements for fatigue will be performed before the first dose of sunitinib and again (4) weeks later to see if there are any changes in physical level of fatigues
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fatigue | — | UNRESOLVED | — |
| Recurrent Renal Cell Cancer | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
| Stage IV Renal Cell Cancer | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| electromyography | Procedure | — | UNRESOLVED |
| sunitinib malate | Drug | Sunitinib | ALIAS |
| survey administration | Other | — | UNRESOLVED |
| transcranial magnetic stimulation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Supportive care (sunitinib malate, neuromuscular testing)
- description
- Patients receive sunitinib malate PO daily for 4 weeks. Patients undergo neuromuscular testing at baseline and on day 28 and complete fatigue assessment at baseline and on days 14 and 28.
- interventionNames
- Procedure: transcranial magnetic stimulation
- Procedure: electromyography
- Other: survey administration
- Drug: sunitinib malate
Primary outcomes (3)
- measure
- Changes of Muscular (Peripheral) Fatigue Maximal Twitch Force (MTF)
- timeFrame
- Baseline and 28 days
- description
- The MTF will be elicited by supramaximal-intensity electrical stimulation of the muscle before and after the sustained contraction (SC). If the muscle is fatigued at the end of the SC, the MTF will be reduced because the ability of muscle to generate force declines with fatigue. If the sunitinib treatment results in minimal muscular fatigue, the MTF will not have as much reduction in the 2nd as that in the 1st session.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven renal cell cancer with metastases; pathology from either primary or metastatic tumor; no histologic subtype restriction * Evidence of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 or evaluable disease * Eastern Cooperative Oncology Group (ECOG) performance score 0 to 1 * Hemoglobin \>= 9 gram/dL * Common Terminology Criteria for Adverse Events (CTCAE) fatigue levels pre-treatment \< 2 * Signed and dated informed consent Exclusion Criteria: * Greater than 2 previous systemic treatments for RCC * Heart failure, New York Heart Association (NYHA) class 3 and 4 * Unstable angina (defined as ongoing use of nitrates or cardiac ischemia in the prior 6 months) * Arrhythmia uncontrolled by medication * Hypertension (\> 160/90 mmHg) not controlled with medical management * Brain metastases or previous cranial radiation, leptomeningeal cancer * Surgery within 2 weeks of study entrance * History of stroke, myasthenia gravis, multiple sclerosis, polyneuropathy * Pregnancy or breast feeding * Central-nervous system active medications, intake or withdrawal of which lowers seizure threshold (determination made in consultation with study's responsible treating physician) * Any history of epilepsy, convulsion or seizure * Medication-resistant epilepsy in a first-degree relative * Cochlear implants or internal pulse generators or cardiac pacemakers or intracardiac lines * Metallic implants in the vicinity of discharging coil in the head or cervical spine * Unexplained fainting spells/syncope or multiple concussions * History of severe head trauma (followed by loss of consciousness) * Implanted brain or spinal cord electrodes/stimulation * Medication infusion device * Frequent/severe headaches or severe migraines * Past or current medical history of diagnosed or undiagnosed tinnitus
References
Publications (0)
Data not yet available
No reference posted for this study.